vs
再生元制药（REGN）与Rocket Companies, Inc.（RKT）财务数据对比。点击上方公司名可切换其他公司
再生元制药的季度营收约是Rocket Companies, Inc.的1.3倍（$3.6B vs $2.7B），再生元制药净利率更高（20.2% vs 2.5%，领先17.6%），Rocket Companies, Inc.同比增速更快（52.2% vs 19.0%），再生元制药自由现金流更多（$848.3M vs $-1.3B），过去两年Rocket Companies, Inc.的营收复合增速更高（39.5% vs 0.8%）
再生元制药是一家总部位于美国纽约州韦斯特切斯特县的生物技术企业，成立于1988年。公司最初围绕神经营养因子及其再生能力开展研究，这也是其名称的由来，后续业务逐步拓展至细胞因子与酪氨酸激酶受体领域，首款产品为VEGF陷阱类药物。
Rocket Companies, Inc.是美国金融科技及住房服务企业，由丹·吉尔伯特创立，总部位于密歇根州底特律市中心。公司依托旗舰子公司Rocket Mortgage跻身美国最大抵押贷款提供商行列，旗下还拥有Redfin、Forsalebyowner.com、Rocket Money等子品牌。
REGN vs RKT — 直观对比
营收规模更大
REGN
是对方的1.3倍
$2.7B
营收增速更快
RKT
高出33.1%
19.0%
净利率更高
REGN
高出17.6%
2.5%
自由现金流更多
REGN
多$2.1B
$-1.3B
两年增速更快
RKT
近两年复合增速
0.8%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $3.6B | $2.7B |
| 净利润 | $727.0M | $68.0M |
| 毛利率 | 89.6% | — |
| 营业利润率 | 17.8% | 6.3% |
| 净利率 | 20.2% | 2.5% |
| 营收同比 | 19.0% | 52.2% |
| 净利润同比 | -10.1% | 100.8% |
| 每股收益（稀释后） | $6.75 | $0.10 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收REGNRKT
| Q1 26 | $3.6B | — | ||
| Q4 25 | $3.9B | $2.7B | ||
| Q3 25 | $3.8B | $1.6B | ||
| Q2 25 | $3.7B | $1.4B | ||
| Q1 25 | $3.0B | $1.0B | ||
| Q4 24 | $3.8B | $1.8B | ||
| Q3 24 | $3.7B | $646.9M | ||
| Q2 24 | $3.5B | $1.3B |
净利润REGNRKT
| Q1 26 | $727.0M | — | ||
| Q4 25 | $844.6M | $68.0M | ||
| Q3 25 | $1.5B | $-123.9M | ||
| Q2 25 | $1.4B | $-1.8M | ||
| Q1 25 | $808.7M | $-10.4M | ||
| Q4 24 | $917.7M | $33.9M | ||
| Q3 24 | $1.3B | $-22.0M | ||
| Q2 24 | $1.4B | $1.3M |
毛利率REGNRKT
| Q1 26 | 89.6% | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 58.9% | ||
| Q3 24 | — | -8.4% | ||
| Q2 24 | — | 47.4% |
营业利润率REGNRKT
| Q1 26 | 17.8% | — | ||
| Q4 25 | 22.7% | 6.3% | ||
| Q3 25 | 27.3% | -11.5% | ||
| Q2 25 | 29.4% | 1.8% | ||
| Q1 25 | 19.5% | -21.5% | ||
| Q4 24 | 26.1% | 38.1% | ||
| Q3 24 | 31.7% | -76.9% | ||
| Q2 24 | 30.2% | 14.8% |
净利率REGNRKT
| Q1 26 | 20.2% | — | ||
| Q4 25 | 21.7% | 2.5% | ||
| Q3 25 | 38.9% | -7.7% | ||
| Q2 25 | 37.9% | -0.1% | ||
| Q1 25 | 26.7% | -1.0% | ||
| Q4 24 | 24.2% | 1.9% | ||
| Q3 24 | 36.0% | -3.4% | ||
| Q2 24 | 40.4% | 0.1% |
每股收益（稀释后）REGNRKT
| Q1 26 | $6.75 | — | ||
| Q4 25 | $7.78 | $0.10 | ||
| Q3 25 | $13.62 | $-0.06 | ||
| Q2 25 | $12.81 | $-0.01 | ||
| Q1 25 | $7.27 | $-0.08 | ||
| Q4 24 | $8.12 | $0.28 | ||
| Q3 24 | $11.54 | $-0.19 | ||
| Q2 24 | $12.41 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $2.7B |
| 总债务越低越好 | $2.0B | — |
| 股东权益账面价值 | $31.4B | $22.9B |
| 总资产 | $40.9B | $60.7B |
| 负债/权益比越低杠杆越低 | 0.06× | — |
8季度趋势，按日历期对齐
现金及短期投资REGNRKT
| Q1 26 | — | — | ||
| Q4 25 | $8.6B | $2.7B | ||
| Q3 25 | $8.4B | $5.8B | ||
| Q2 25 | $7.5B | $5.1B | ||
| Q1 25 | $8.3B | $1.4B | ||
| Q4 24 | $9.0B | $1.3B | ||
| Q3 24 | $9.8B | $1.2B | ||
| Q2 24 | $9.8B | $1.3B |
总债务REGNRKT
| Q1 26 | $2.0B | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益REGNRKT
| Q1 26 | $31.4B | — | ||
| Q4 25 | $31.3B | $22.9B | ||
| Q3 25 | $31.0B | $8.9B | ||
| Q2 25 | $29.9B | $7.4B | ||
| Q1 25 | $29.4B | $8.6B | ||
| Q4 24 | $29.4B | $9.0B | ||
| Q3 24 | $29.3B | $8.4B | ||
| Q2 24 | $28.2B | $8.8B |
总资产REGNRKT
| Q1 26 | $40.9B | — | ||
| Q4 25 | $40.6B | $60.7B | ||
| Q3 25 | $40.2B | $33.6B | ||
| Q2 25 | $38.2B | $30.4B | ||
| Q1 25 | $37.5B | $25.3B | ||
| Q4 24 | $37.8B | $24.5B | ||
| Q3 24 | $37.4B | $25.1B | ||
| Q2 24 | $36.1B | $23.6B |
负债/权益比REGNRKT
| Q1 26 | 0.06× | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $1.1B | $-1.2B |
| 自由现金流经营现金流 - 资本支出 | $848.3M | $-1.3B |
| 自由现金流率自由现金流/营收 | 23.5% | -47.2% |
| 资本支出强度资本支出/营收 | 6.4% | 1.5% |
| 现金转化率经营现金流/净利润 | 1.48× | -18.08× |
| 过去12个月自由现金流最近4个季度 | $4.1B | $-4.0B |
8季度趋势，按日历期对齐
经营现金流REGNRKT
| Q1 26 | $1.1B | — | ||
| Q4 25 | $1.2B | $-1.2B | ||
| Q3 25 | $1.6B | $-50.3M | ||
| Q2 25 | $1.1B | $-1.9B | ||
| Q1 25 | $1.0B | $-797.0M | ||
| Q4 24 | $1.3B | $1.8B | ||
| Q3 24 | $1.3B | $-1.3B | ||
| Q2 24 | $354.0M | $-122.3M |
自由现金流REGNRKT
| Q1 26 | $848.3M | — | ||
| Q4 25 | $922.0M | $-1.3B | ||
| Q3 25 | $1.4B | $-71.8M | ||
| Q2 25 | $925.4M | $-1.9B | ||
| Q1 25 | $815.8M | $-811.0M | ||
| Q4 24 | $1.1B | $1.8B | ||
| Q3 24 | $1.0B | $-1.4B | ||
| Q2 24 | $173.5M | $-138.3M |
自由现金流率REGNRKT
| Q1 26 | 23.5% | — | ||
| Q4 25 | 23.7% | -47.2% | ||
| Q3 25 | 37.8% | -4.5% | ||
| Q2 25 | 25.2% | -137.2% | ||
| Q1 25 | 26.9% | -78.2% | ||
| Q4 24 | 28.1% | 103.1% | ||
| Q3 24 | 28.2% | -209.6% | ||
| Q2 24 | 4.9% | -10.6% |
资本支出强度REGNRKT
| Q1 26 | 6.4% | — | ||
| Q4 25 | 6.4% | 1.5% | ||
| Q3 25 | 5.4% | 1.3% | ||
| Q2 25 | 6.0% | 1.1% | ||
| Q1 25 | 7.6% | 1.4% | ||
| Q4 24 | 5.3% | 1.1% | ||
| Q3 24 | 6.5% | 2.9% | ||
| Q2 24 | 5.1% | 1.2% |
现金转化率REGNRKT
| Q1 26 | 1.48× | — | ||
| Q4 25 | 1.39× | -18.08× | ||
| Q3 25 | 1.11× | — | ||
| Q2 25 | 0.82× | — | ||
| Q1 25 | 1.29× | — | ||
| Q4 24 | 1.38× | 54.42× | ||
| Q3 24 | 0.96× | — | ||
| Q2 24 | 0.25× | -94.46× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
REGN
| Sanofi | $1.6B | 45% |
| Other | $507.0M | 14% |
| EYLEA - U.S | $473.0M | 13% |
| Bayer | $287.0M | 8% |
| Libtayo ® - U.S | $286.0M | 8% |
| Other revenue | $171.0M | 5% |
| Libtayo - ROW* | $152.0M | 4% |
| Praluent - U.S | $67.0M | 2% |
| Evkeeza ® - U.S | $46.0M | 1% |
| Lynozyfic ® - Global | $11.0M | 0% |
RKT
| Other | $1.4B | 51% |
| Direct To Customer Segment | $945.8M | 35% |
| Partner Network Segment | $216.7M | 8% |
| Subscription Revenue | $91.3M | 3% |
| Closing Fees | $47.1M | 2% |
| Appraisal Revenue | $10.7M | 0% |
